Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections
about
Drug Points: tachycardia associated with moxifloxacinAntimicrobial safety: focus on fluoroquinolonesCefepimeA Prospective Study of the Efficacy, Safety and Pharmacokinetics of Enteral Moxifloxacin in the Treatment of Hemodialysis Patients with Pneumonia.What do the new antimicrobials offer? Weighing the advantages and disadvantages compared with traditional agents.Levofloxacin-based triple therapy in first-line treatment for Helicobacter pylori eradication.Moxifloxacin pharmacokinetic profile and efficacy evaluation in empiric treatment of community-acquired pneumonia.Treatment of bacterial skin and skin structure infections.Clinical relevance and management of drug-related QT interval prolongation.Emerging drugs for ophthalmic diseases.A brief review of moxifloxacin in the treatment of elderly patients with community-acquired pneumonia (CAP).Exposure to antibacterial agents with QT liability in 14 European countries: trends over an 8-year periodEfficacy and safety of moxifloxacin in acute exacerbations of chronic bronchitis and COPD: a systematic review and meta-analysisLevofloxacin and proton pump inhibitor-based triple therapy versus standard triple first-line therapy for Helicobacter pylori eradication.Analytical Methods for Determining Third and Fourth Generation Fluoroquinolones: A ReviewEffect of utilization policies for fluoroquinolones: a pilot study in nova scotia hospitals.Discrepancy between uptake and intracellular activity of moxifloxacin in a Staphylococcus aureus-human THP-1 monocytic cell modelDevelopment and validation of spectrophotometric, atomic absorption and kinetic methods for determination of moxifloxacin hydrochloride.Activities of ciprofloxacin and moxifloxacin against Stenotrophomonas maltophilia and emergence of resistant mutants in an in vitro pharmacokinetic-pharmacodynamic model.A validated HPTLC method for estimation of moxifloxacin hydrochloride in tabletsPhotodegradation assessment of ciprofloxacin, moxifloxacin, norfloxacin and ofloxacin in the presence of excipients from tablets by UPLC-MS/MS and DSC.Efficacy and safety of short course (5-day) moxifloxacin vs 7-day ceftriaxone in the treatment of acute exacerbations of chronic bronchitis (AECB).Comparison of the once-daily levofloxacin-containing triple therapy with the twice-daily standard triple therapy for first-line Helicobacter pylori eradication: a prospective randomised study.Efficacy and safety of adjunctive local moxifloxacin delivery in the treatment of periodontitis.Mono, dual and triple moxifloxacin-based therapies for Helicobacter pylori eradication.Short treatment durations for acute bacterial rhinosinusitis: Five days of gemifloxacin versus 7 days of gemifloxacin.Sinus tissue concentration of moxifloxacin after a single oral dose.Comparison of rifampicin and moxifloxacin efficacy in an experimental model of animal brucellosis.Switch from intravenous to enteral moxifloxacin in critically ill patients: a pilot study.Design synthesis and antibacterial activity studies of new thiadiazoloquinolone compounds.Synthesis and Antibacterial Activity of Some Novel 4-Oxopyrido[2,3-a]phenothiazines
P2860
Q28174956-9F75710C-A512-42E7-A2F1-B95B24A2C67FQ28255152-E77D30EB-B019-4250-9949-A297F6C88E9FQ29040262-EBD72A7B-5EAE-4BA4-BA81-90B29CED1B9EQ33874674-638FDACA-7BB6-4B43-8BE1-AB98448334D4Q34193591-6F8A7CC6-F556-4E70-9370-627BCE188C76Q34570815-D0B8E355-8C21-4989-A4A7-B2376406EFA9Q35168927-60EC557F-0ACD-440C-81E4-5C86D5013C4EQ35183731-006F12EA-5C26-4587-A5A1-D0534FAEA482Q35186542-CB316FFE-60C6-40E7-A7B0-A04A2E65C982Q35581180-D57FF80A-590E-434A-A150-5FC02CBFA576Q37017387-4AB2A4CE-7A13-4861-8060-F2BBF2A76B50Q37156289-4D90A583-4FE0-438C-9A78-369D5A7886B5Q37629535-AE44C25B-6D81-4594-A210-0027D51E2021Q38200052-42C6E4AE-11C6-4AD7-A8F7-57791F689628Q39143340-87AAEE0A-4B29-4A1D-A8EE-E9E51D14C115Q39210974-622D7808-8D17-4EF6-BAA9-F41BCAB8619EQ39651212-372FDC7D-C8D9-40A3-93CE-BED9A053D513Q39827030-91050973-14F1-4C5D-90A1-589C5AB0A1D7Q40621865-BDD34253-3188-4117-8CC4-D713D2F639A8Q40829013-23CD071E-B116-4DAA-836D-35E088068B0EQ42134091-F436F88F-5DA2-4AEE-B239-A5837F39E389Q42694701-106BE2B1-5D19-42F4-A471-78D42EB7EE4EQ42905753-53BEB4B0-9ED0-44E0-B53F-37D2308FBFD2Q43810745-42E3F11B-0A5E-487D-8627-54B81803353FQ43904283-795EAB80-841E-4A59-BCBD-5D31BD747A2DQ44089196-0F9722F8-7298-4B09-A759-9950DDED43A4Q44782882-DF513EDD-7163-40BE-AB9A-7F4CDD3B9B9CQ46699483-34023F3F-1EBA-4106-9B25-BF965594D6DBQ49159581-7BE81440-16E4-482D-A59C-A07259A42BD1Q54295509-CF6E0FB2-FB78-412F-A830-74F76C5FCD5CQ57787870-4723B8AC-92C4-4749-B4AE-C555ED4C9838
P2860
Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Moxifloxacin: a review of its ...... d respiratory tract infections
@ast
Moxifloxacin: a review of its ...... d respiratory tract infections
@en
Moxifloxacin: a review of its ...... d respiratory tract infections
@nl
type
label
Moxifloxacin: a review of its ...... d respiratory tract infections
@ast
Moxifloxacin: a review of its ...... d respiratory tract infections
@en
Moxifloxacin: a review of its ...... d respiratory tract infections
@nl
prefLabel
Moxifloxacin: a review of its ...... d respiratory tract infections
@ast
Moxifloxacin: a review of its ...... d respiratory tract infections
@en
Moxifloxacin: a review of its ...... d respiratory tract infections
@nl
P2860
P1433
P1476
Moxifloxacin: a review of its ...... d respiratory tract infections
@en
P2093
P2860
P304
P356
10.2165/00003495-200059010-00010
P407
P577
2000-01-01T00:00:00Z
P6179
1004361699